Through its Rapid Evolution Platform, the North Carolina-based plant biotechnology startup employs AI-powered genomic ...

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the ...

Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa ...

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is one of the top long-term biotechnology stocks to buy. On October 17, Piper Sandler ...

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be ...

For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said ...

Climate change is affecting farming all over the world, and solutions are seldom simple. But if you could plant crops that resisted the heat, cold or drought instead of moving a thousand miles away, ...

Avalo Therapeutics, formerly Cerecor, readjusted almost its entire pipeline Wednesday, just weeks after the biotech's CEO and finance chief hit the exit. The culling includes winding down the ...

Avalo Therapeutics' value mostly hinges on AVTX-009. This is an IL-1β mAb in a Phase 2 LOTUS trial for hidradenitis suppurativa. This Phase 2 trial should give us topline results by mid-2026, which I ...

Avalo Therapeutics is handing over more than $22 million in stock and cash to acquire AlmataBio for a phase 2-ready monoclonal antibody for hidradenitis suppurativa (HS). The anti-IL-1β mAb, dubbed ...

The latest price target for Avalo Therapeutics (NASDAQ:AVTX) was reported by Jefferies on March 25, 2025. The analyst firm set a price target for $23.00 expecting AVTX to rise to within 12 months (a ...